CSIMarket Company Name, Ticker, Competitors, else..
 
Mink Therapeutics Inc   (NASDAQ: INKT)
Other Ticker:  
 
 
Price: $8.4880 $0.31 3.829%
Day's High: $8.488 Week Perf: 10.81 %
Day's Low: $ 8.18 30 Day Perf: -9.51 %
Volume (M): 3 52 Wk High: $ 13.79
Volume (M$): $ 21 52 Wk Avg: $1.95
Open: $8.37 52 Wk Low: $0.46



 Market Capitalization (Millions $) 336
 Shares Outstanding (Millions) 40
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Mink Therapeutics Inc
Mink Therapeutics Inc is a biotechnology company that focuses on developing targeted mRNA therapies for treating various diseases. The company's approach involves using modified mRNA molecules to produce therapeutic proteins within the patient's cells, aiming to address the underlying causes of diseases at a genetic level. Mink Therapeutics aims to leverage mRNA technology to create personalized treatments for a range of conditions, including rare genetic disorders, cancer, and infectious diseases. The company utilizes its proprietary platform and expertise in mRNA therapeutics to advance its drug development pipeline and potentially revolutionize the field of gene therapy.


   Company Address: 149 Fifth Avenue New York 10010 NY
   Company Phone Number: 994-8250   Stock Exchange / Ticker: NASDAQ INKT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CCCC   -6.02%    
CRIS        1.79% 
ELUT        6% 
IKNA   -4.96%    
INBX        7.55% 
IOVA   -3.75%    
• View Complete Report
   



Clinical Study

MiNK Therapeutics Unveils Promising Allo-iNKT Cell Therapy Combination to Tackle Advanced Gastroesophageal Cancers at...

Published Thu, Jan 23 2025 7:44 PM UTC

In a significant advancement in cancer treatment, MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering clinical-stage biopharmaceutical company, showcased its innovative approach to tackling advanced gastroesophageal cancers at the esteemed American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium held in San Francisco, California. The company is com...
Clinical Study

MiNK Therapeutics' Clinical Data Reveals Promising Results for AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Refractory Gastric Cancer Therapy

Published Wed, May 22 2024 11:30 AM UTC

MiNK Therapeutics Presents Promising Clinical Activity of AgenT-797 in Severe Acute Respiratory Distress Syndrome (ARDS) and Gastric Cancer PatientsNew York, May 22, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a leading clinical-stage biopharmaceutical company specializing in allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other ...
Financing Agreement

MiNK Therapeutics Raises $5.8 Million in Private Placement and Bolsters Clinical Trials with Board Observer Appointment

Published Mon, May 13 2024 11:30 AM UTC

MiNK Therapeutics Secures $5.8 Million in Private Placement and Adds Board Observer for Accelerated Clinical Trials of MiNK-215
NEW YORK, May 13, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a trailblazing clinical-stage biopharmaceutical company focused on the development, discovery, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT)...
Clinical Study

New York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed promising preclinical data for its investigational iNKT cell therapy, MiNK-215, targeting colorectal cancer liver metastases. The announcement was made during the American Association for Cancer Research (AACR) Meeting held in San Diego, CA.MiNK Therapeutics is focused on developing and commercia...

Published Mon, Apr 8 2024 4:00 PM UTC

MiNK Therapeutics Announces promising preclinical activity of MiNK-215 against colorectal cancer liver metastases at AACRNew York, April 08, 2024 - MiNK Therapeutics, a clinical-stage biopharmaceutical company, revealed promising preclinical data for its investigational iNKT cell therapy, MiNK-215, targeting colorectal cancer liver metastases. The announcement was made durin...
Clinical Study

AgenT-797: A Promising Breakthrough in Overcoming Immune Checkpoint Inhibitor Resistance in Refractory Gastric Cancer

Published Wed, Feb 14 2024 1:00 PM UTC

MiNK Therapeutics, a clinical-stage biopharmaceutical company, recently announced the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer. Led by Dr. Yelena Janjigian at the Memorial Sloan Kettering Cancer Center, this study aims to build upon the remarkable findings from MiNK s previous clinical trial, demonstrating the ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com